About this trial

The oropharyngeal areas mainly comprises of the tonsil, base tongue (BOT), soft palate and the posterior pharyngeal wall. Traditionally, surgical resection of oropharyngeal cancers (OPC) was a standard procedure, often performed through mutilating incisions with mandibulotomies, rendering significant post-operative functional deficits. Over the past 2 decades, there has been a major shift in treatment strategy with a majority of these cancers now being treated by primary concurrent chemoradiation (CCRT) with a trend towards organ and function preservation.

Eligibility criteria

Qualifiers

Histopathology proven diagnosis of squamous cell carcinoma of the oropharynx, localized to the tonsil and/or lateralized tongue-base

ECOG Performance Status ≤2

Age ≥18 to 70 years

Anesthetic fitness obtained for surgery under general anesthesia

Disqualifiers

Prior head and neck malignancy

Prior invasive malignancy, unless disease free for a minimum of 3 years

Prior chemotherapy for a different cancer administered within 3 years prior to registration

Patients who have received any neoadjuvant/ induction chemotherapy

Trial design

Treatments tested in this trial

  • Surgery with or without Neck Dissection
  • Radiation
  • Cisplatin based chemotherpay

Treatment groups

498 Participants
are divided into 2 treatment groups

Locations

1
Tata Memorial Hospital400012, MumbaiMaharashtra, India

Sponsors and collaborators

Tata Memorial Centre

Lead sponsor

All India Institute of Medical Sciences

Collaborator

Amrita Institute of Medical Sciences & Research Center

Collaborator